International consensus statement for anti-tumour necrosis factor agents in ankylosing spondylitis

The "Assessments in ankylosing spondylitis Working Group" (ASAS) have recently reviewed the use of anti-tumour necrosis factor alpha agents (anti-TNFa) for treating patients with ankylosing spondylitis (AS). The working party conducted an evaluation of published reports in combination with expert opinion, including a Delphi exercise, and a consensus meeting, in order to obtain an international consensus regarding anti-TNFa therapy in AS.The final consensus comprised the following requirements:(1) For the initiation of anti-TNFa therapy:...